WAVE Life Sciences (NASDAQ:WVE) Insider Sells $25,326.35 in Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 1,883 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $25,326.35. Following the sale, the insider directly owned 61,867 shares of the company’s stock, valued at approximately $832,111.15. This represents a 2.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Chris Francis also recently made the following trade(s):

• On Friday, January 2nd, Chris Francis sold 9,375 shares of WAVE Life Sciences stock. The shares were sold at an average price of $16.03, for a total value of $150,281.25.
• On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The stock was sold at an average price of $14.57, for a total transaction of $6,425,821.67.

WAVE Life Sciences Stock Performance

Shares of WAVE Life Sciences stock traded down $0.32 during trading on Wednesday, hitting $13.27. 2,543,164 shares of the company’s stock were exchanged, compared to its average volume of 3,266,049. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -17.69 and a beta of -1.78. The business has a 50-day simple moving average of $14.99 and a 200-day simple moving average of $10.38. WAVE Life Sciences Ltd. has a 52-week low of $5.28 and a 52-week high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The business had revenue of $7.61 million during the quarter, compared to analysts’ expectations of $9.85 million. WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. On average, equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

WVE has been the subject of several recent analyst reports. Oppenheimer lifted their price target on WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Raymond James Financial restated an “outperform” rating and set a $21.00 price objective on shares of WAVE Life Sciences in a research report on Monday, December 8th. Leerink Partners reiterated an “outperform” rating on shares of WAVE Life Sciences in a research report on Monday, December 8th. Wells Fargo & Company increased their target price on WAVE Life Sciences from $16.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.69.

Institutional Trading of WAVE Life Sciences

Several large investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. increased its position in WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock worth $97,607,000 after purchasing an additional 2,500,000 shares during the last quarter. 683 Capital Management LLC grew its stake in shares of WAVE Life Sciences by 4.5% in the 2nd quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company’s stock valued at $26,650,000 after buying an additional 175,000 shares during the period. Primecap Management Co. CA increased its stake in WAVE Life Sciences by 115.7% during the fourth quarter. Primecap Management Co. CA now owns 4,095,282 shares of the company’s stock worth $69,620,000 after acquiring an additional 2,196,632 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of WAVE Life Sciences by 678,144.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after purchasing an additional 3,750,140 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of WAVE Life Sciences by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 3,573,746 shares of the company’s stock worth $60,754,000 after purchasing an additional 433,910 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.